SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
16 references·0 citing·43 second hop
Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (2017)Cost-effectiveness Analysis of Nivolumab …Cost-Effectiveness of Immune Checkpoint Inhibition inBRAFWild-Type Advanced Melanoma (2017)Cost-Effectiveness of Immune …Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses (2016)Recommendations for Conduct, …Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015 (2016)Global, Regional, and Nationa…Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer (2016)Financial Insolvency as a Ris…Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes (2016)Economic evaluation of nivolu…Comparison of Treatment Costs for Breast Cancer, by Tumor Stage and Type of Service. (2016)Comparison of Treatment Costs…A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing (2016)A Cost-Effectiveness Analysis…Pricing in the Market for Anticancer Drugs (2015)Pricing in the Market for Ant…The Economic Burden of Head and Neck Cancer: A Systematic Literature Review (2014)The Economic Burden of Head a…The Financial Toxicity of Cancer Treatment: A Pilot Study Assessing Out-of-Pocket Expenses and the Insured Cancer Patient's Experience (2013)The Financial Toxicity of Can…Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study (2010)Population preference values …What Does the Value of Modern Medicine Say About the $50,000 per Quality-Adjusted Life-Year Decision Rule? (2008)What Does the Value of Modern…Evaluation of Trends in the Cost of Initial Cancer Treatment (2008)Evaluation of Trends in the C…Health state utilities for metastatic breast cancer (2006)Health state utilities for me…The Economic Cost of Squamous Cell Cancer of the Head and Neck (2004)The Economic Cost of Squamous…A comparative economic analysis of pegylated liposomal doxorubicin versus topotecan in ovarian cancer in the USA and the UK (2002)A comparative economic analys…Cost-Effectiveness in Health and Medicine (1996)Quality of life and pharmacoeconomics in clinical trials (1996)EQ-SD: a measure of health status from the EuroQol Group (2001)Health-state utility values in breast cancer (2010)Estimating Health-State Utility for Economic Models in Clinical Studies: An ISPOR Good Research Practices Task Force Report (2016)Health state utilities in non–small cell lung cancer: An international study (2016)Health Care Financing Review (1980)The Distinction Between Cost and Charges (1982)Estimating Health Care Costs Related to Cancer Treatment From SEER-Medicare Data (2002)National Estimates of Out-of-Pocket Health Care Expenditure Burdens Among Nonelderly Adults With Cancer: 2001 to 2008 (2011)The economic burden of prostate cancer (2011)Free for All? Lessons from the RAND Health Insurance Experiment (1995)Willingness to Pay for a Quality-adjusted Life Year (2000)A community empowerment approach to the HIV response among sex workers: effectiveness, challenges, and considerations for implementation and scale-up (2014)The cost of multiple sclerosis drugs in the US and the pharmaceutical industry (2015)A Health Opportunity Cost Threshold for Cost-Effectiveness Analysis in the United States (2020)Mental Accounting and Consumer Choice (1985)Fairness as a Constraint on Profit Seeking: Entitlements in the Market (2000)Mental Accounting and Consumer Choice (2008)The high price of anticancer drugs: origins, implications, barriers, solutions (2017)Financial toxicity in cancer care: Prevalence, causes, consequences, and reduction strategies (2019)How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment (2021)Cumulative Impact of Sustained Economic Hardship on Physical, Cognitive, Psychological, and Social Functioning (1997)Financial Hardships Experienced by Cancer Survivors: A Systematic Review (2016)The financial burden and distress of patients with cancer: Understanding and stepping‐up action on the financial toxicity of cancer treatment (2018)American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options (2015)Costs of cancer along the care continuum: What we can expect based on recent literature (2018)Global treatment costs of breast cancer by stage: A systematic review (2018)Increased healthcare costs by later stage cancer diagnosis (2022)Methods for the Economic Evaluation of Health Care Programmes (2005)Understanding Costs of Care in the Operating Room (2018)Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force (2022)Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations (2022)Patient Time Costs Associated With Cancer Care (2007)Productivity Costs of Cancer Mortality in the United States: 2000–2020 (2008)Projections of the Cost of Cancer Care in the United States: 2010-2020 (2011)Comparison of the Financial Burden of Survivors of Head and Neck Cancer With Other Cancer Survivors (2019)Patient-reported financial toxicity and adverse medical consequences in head and neck cancer (2019)Understanding financial toxicity in head and neck cancer survivors (2019)Measuring financial toxicity as a clinically relevant patient‐reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST) (2016)Measuring population ageing: an analysis of the Global Burden of Disease Study 2017 (2019)Mindfulness-Based Cognitive Therapy for Psychological Distress, Fear of Cancer Recurrence, Fatigue, Spiritual Well-Being, and Quality of Life in Patients With Breast Cancer—A Randomized Controlled Trial (2020)Population ageing and mortality during 1990–2017: A global decomposition analysis (2020)
this work references cited by second hop

References

  • 2016Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 20156,217 cited
  • 2016Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses3,063 cited
  • 2013The Financial Toxicity of Cancer Treatment: A Pilot Study Assessing Out-of-Pocket Expenses and the Insured Cancer Patient's Experience1,133 cited
  • 2016Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer917 cited
  • 2008What Does the Value of Modern Medicine Say About the $50,000 per Quality-Adjusted Life-Year Decision Rule?578 cited
  • 2015Pricing in the Market for Anticancer Drugs452 cited
  • 2008Evaluation of Trends in the Cost of Initial Cancer Treatment388 cited
  • 2006Health state utilities for metastatic breast cancer356 cited
  • 2016Comparison of Treatment Costs for Breast Cancer, by Tumor Stage and Type of Service.256 cited
  • 2014The Economic Burden of Head and Neck Cancer: A Systematic Literature Review179 cited
  • 2010Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study112 cited
  • 2017Cost-Effectiveness of Immune Checkpoint Inhibition inBRAFWild-Type Advanced Melanoma108 cited
  • 2016A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

89 cited
  • 2004The Economic Cost of Squamous Cell Cancer of the Head and Neck85 cited
  • 2016Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes77 cited
  • 2002A comparative economic analysis of pegylated liposomal doxorubicin versus topotecan in ovarian cancer in the USA and the UK76 cited
  • Cited by

    No citing works inside the corpus for this window.